Gynaecological Cancers: Immunotherapy and Novel Targeted Drug Appear Beneficial in Group of Women with Early-Stage Disease #ESMO24
Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial (1) and cervical cancers (2) who gain clinically meaningful benefit from adding immunotherapy to current standard treatments,…
First evidence that Breastfeeding after Breast Cancer is safe #ESMO24 in Barcelona
According to two international studies presented at the ESMO Congress 2024 in Barcelona, women who breastfeed after receiving treatment for breast cancer, including those with a germline BRCA mutation (an…
Lower dose of mpox vaccine is safe and generates six-week antibody response equivalent to standard regimen
Colorized scanning electron micrograph of mpox virus particles (blue) on the surface of infected VERO E6 cells (pink). NIAID A dose-sparing intradermal mpox vaccination regimen was safe and generated an…